Hi everyone,
Just thought to briefly put ZLD news over the past 2 years. Most of the price sensitive announcements and their highlights, we are on track with some delays but definitely the future looks promising!
-------------------------------------------------------------
04/09/2018 Zelda Forms New Partnership to Access German Market
Ordinary Shares: 755,341,934
Options: 49,000,000
1,500,000 ($0.04 – 6/2/2020) - *4,500,000 ($0.04 – 6/2/2020) - 1,000,000 ($0.125 – 22/8/2021) - *3,000,000 ($0.125 – 22/8/2021)
40,000,000($0.03125 – 17/11/2021)
• Provides Zelda with ready access to the rapidly growing German market upon successful completion of clinical trials
-------------------------------------------------------------
26/09/2018 First Patient Dosed in Zelda Insomnia Trial
• Preliminary results expected 1H-2019
-------------------------------------------------------------
10/10/2018 US Autism Observational Study Underway
• Preliminary results expected first half of 2019
-------------------------------------------------------------
06/12/2018 SUD: SUDA Enters Agreement To Develop Cannabinoid Spray
*No idea what happened to the money invested here!
• Under the terms of the Agreement Zelda will pay SUDA an optionfee of $200,000 consisting of an upfront of $100,000 and a further $100,000 indownstream milestone payments. Zelda will also fund the formulation work. The 24-month option provides ZELDA with an exclusive right to extend the Agreement and toenter into a global development and licensing agreement for the oral spray formulationsdeveloped by SUDA
-------------------------------------------------------------
06/03/2019 Aus Patent For Novel Prognostic Marker for Breast Cancer
Ordinary Shares: 755,341,934 Options: 85,700,000
• Patent provides protection until 2038
-------------------------------------------------------------
12/03/2019 Zelda Partners with Ilera HealthCare
Ordinary Shares: 755,341,934 Options: 85,700,000
• Provides Zelda access to established medicinal cannabis markets in US states with >80,000 registered patients.
-------------------------------------------------------------
02/07/2019 Zelda Granted Approval for Opioid Reduction Trial
Ordinary Shares: 755,341,934 Options: 85,700,000
• Trial at St Vincent’s Hospital Melbourne to begin immediately with final results by Q4 2019
• Outcomes will feed in to larger Phase II trial
-------------------------------------------------------------
18/07/2019 Zelda Collaborates with Emerald Clinics
• Zelda will pay Emerald an initial fee of $40,000 to access existing de-identified data for patients prescribed medicinal cannabis for treatment of pain and/or insomnia, whilesubscription fees for the additional data-modules will be negotiated at a later date.
-------------------------------------------------------------
22/08/2019 Zeldas Autism Observational Study Recruits 100th Participant
Ordinary Shares: 757,341,934 Options: 83,700,000
• Currently, there are 103 participants enrolled in the study, with the final target of 150 expected by early 2020.
-------------------------------------------------------------
09/10/2019 Zelda to merge with US-based Ilera Therapeutics
Ordinary Shares: 757,341,934 Options: 83,700,000
(a) 113,601,290 fully paid ordinary shares in the Company (Consideration Shares); and
(b) 362,620,322 Class A Performance Rights; Performance Rights received bythe Company or its subsidiaries from US-based product sales exceeds US$1,000,000.
(c) 362,620,322 Class B Performance Rights, Performance Rights received bythe Company or its subsidiaries from US-based product sales exceeds US$2,500,000
-------------------------------------------------------------
07/11/2019 Zeldas Phase II Insomnia Clinical Trial Fully Enrolled
• Preliminary results expected by February 2020
-------------------------------------------------------------
21/11/2019 Agreement with Health House to Distribute Zelda Products
Ordinary Shares: 758,841,934 Options: 83,596,667
• Plans are underway to launch HOPE® and the Insomnia product in global markets from early 2020
-------------------------------------------------------------
04/12/2019 Zelira Therapeutics expands HOPE distribution in the U.S.A
• Available in Louisiana, a state with approximately 5 million residents, in First Quarter 2020
-------------------------------------------------------------
05/02/2020 Zelira Successfully Completes Capital Raising of $4.6M
• Zelira has successfully completed a placement of 91,770,000 fully-paid ordinary shares at a share price of A$0.05 to Australianand International investors. The Placement will raise A$4,588,500 before costs (“Placement”).
-------------------------------------------------------------
19/02/2020 Zelira Meets Primary Endpoints for Insomnia Trial
• Poised to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020
• Expands Zelira’s product portfolio alongside the HOPETM product range
-------------------------------------------------------------
27/02/2020 Phase 1 Opioid Reduction Clinical Trial Fully Enrolled
• Dosing to be completed by end of April 2020
• Study report expected by mid 2020
-------------------------------------------------------------
28/02/2020 Appendix 4D & FY20 Interim Financial Report
* Lots of details, if interested here is the link to the report:
https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=02209076
-------------------------------------------------------------
07/04/2020 Insomnia Trial Meets Primary and Secondary Endpoints
• On-track to launch world’s first clinically validated medicinal cannabis product for insomnia in 2020.
-------------------------------------------------------------
30/04/2020 March 2020 Quarterly Report
• Insomnia trial successfully meets clinical endpoints
• Opioid sparing trial completes recruitment and dosing
• Autism observational study completes recruitment• Collaboration progressing with The Parkinson’s Foundation
• Capital Raise & Revenues
-------------------------------------------------------------
26/05/2020 TasAlk to Manufacture Zeliras Insomnia and HOPE products
• Australian launch of Insomnia and HOPE™ medicinal cannabis products on-track for Q3 2020, whichwould transform Zelira into a fully commercial, revenue generating company in the US and Australia
I will keep updating this with price sensitive news/milestones!
GLTAH & "ALWAYS" DYOR
Expand
(20min delay)